TL;DR
This study investigates the neuropathological changes around deep brain stimulation (DBS) leads in Parkinson's disease patients. Researchers found that phosphorylated TDP-43 (p-TDP-43) and phosphorylated tau (p-tau) proteins accumulate specifically around the tips of DBS electrodes, suggesting a novel protein aggregation mechanism triggered by chronic electrical stimulation.
What Problem Does This Paper Address?
Deep brain stimulation (DBS) is a highly effective surgical treatment for movement disorders like Parkinson's disease (PD). While its clinical benefits are well-established, previous postmortem studies have indicated that the presence of DBS electrodes can induce localized tissue reactions, such as gliosis and inflammation, around the electrode tracts. However, the specific molecular changes occurring at the electrode-tissue interface, particularly concerning the deposition of abnormal proteins implicated in neurodegenerative diseases, remained largely unexplored. This paper aims to fill this gap by examining the presence of two key proteins, phosphorylated TDP-43 (p-TDP-43) and phosphorylated tau (p-tau), at the site of DBS electrode termination.
Methods
The study employed postmortem neuropathological examination of brain tissue from two Japanese patients diagnosed with Parkinson's disease who had undergone DBS implantation. The researchers performed detailed histological analysis using Hematoxylin and Eosin (HE) staining and Azan staining to visualize general tissue architecture, gliosis, and connective tissue. Crucially, they utilized immunohistochemistry with specific antibodies against glial fibrillary acidic protein (GFAP) to identify astrogliosis, anti-phosphorylated tau (p-tau) antibodies, and anti-phosphorylated TDP-43 (p-TDP-43) antibodies to detect the presence and distribution of these abnormal protein aggregates. The examination focused specifically on the area immediately surrounding the tips of the DBS electrodes.
Datasets
Not discussed in the paper. The study analyzed postmortem brain tissue from two human patients.
Key Insights and Ideas
- DBS as a Trigger for Protein Aggregation: The most significant finding is the localized accumulation of p-TDP-43 and p-tau specifically around the DBS lead tips. This suggests that the chronic, repetitive electrical stimulation from DBS, rather than just general aging or PD pathology, can directly induce or exacerbate the aggregation of these disease-associated proteins.
- Novel Pathological Change: This is the first study to report the deposition of p-TDP-43 around a DBS electrode. This discovery opens up a new avenue for understanding the complex interactions between neurostimulation and proteinopathy.
- Differential Protein Deposition: While both p-TDP-43 and p-tau were found, they did not appear to colocalize. This hints at potentially distinct or independent mechanisms driving their accumulation in response to DBS.
- Localized Effect: The observed protein deposition was highly localized to the electrode termination sites, with no significant p-TDP-43 found in other brain regions or the spinal cord, further strengthening the link to the DBS intervention itself.
Key Results
- Case 1: In a patient who received DBS in the left ventral intermediate nucleus of the thalamus, neuropathological examination revealed fibrous gliosis, mild lymphocyte infiltration, and hemosiderin deposition around the DBS lead tip. Importantly, p-tau and p-TDP-43 positive deposits were visible in the neuropil adjacent to the electrode termination site.
- Case 2: In a patient with bilateral subthalamic nucleus DBS, similar findings of fibrous gliosis and mild lymphocyte infiltration were observed. P-tau positive structures were present around the electrode tip, and tiny p-TDP-43 positive aggregates were also detected.
- Absence of p-TDP-43 Elsewhere: In both cases, p-TDP-43 positive structures were not observed in other brain regions, including areas typically affected by TDP-43 proteinopathies like ALS or LATE.
Limitations and Future Work
- Small Sample Size: The study is based on only two cases, which significantly limits the generalizability of the findings.
- Lack of Control Group: The study did not include a control group of PD patients who did not undergo DBS, making it challenging to definitively attribute the observed protein deposition solely to DBS.
- Future Work: The authors emphasize the need for examining further DBS cases to elucidate the underlying mechanisms of this novel protein aggregation phenomenon. They suggest that understanding how chronic electrical stimulation influences protein aggregation could lead to insights into modifying the physiological effects of DBS and potentially mitigating adverse outcomes. Further research could explore the temporal dynamics of this deposition and its potential impact on DBS efficacy or side effects.
Summary updated